Press Releases

Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been…

Key Highlights This European Authorisation reinforces Chiesi’s commitment to provide a broad range of formulations and devices to asthma patients. NEXThaler® is a dry powder inhaler (DPI), specifically designed for Chiesi’s extrafine formulations. With the addition of the DPI in the asthma…

PARMA, Italy – June 5, 2026 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European Commission (EC) has approved lomitapide capsules for use in children 5…

Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of lomitapide to include children 5 years of age and older with HoFH PARMA, Italy – March 30, 2026 –…

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT) With this decision, announced ahead of Fabry Disease…

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by the EC, this dosing regimen would reduce the burden to eligible patients, their…

Key Highlights The two studies presented at BTS demonstrated therapeutic equivalence and similar safety profiles of Chiesi’s beclometasone dipropionate/ formoterol fumarate product formulated with next generation HFA-152a propellant, compared to the current HFA-134a formulation, in two different…

Key highlights: Successfully completed the TRECOS Phase III study*, supporting the long-term safety of Chiesi’s carbon minimal pressurized metered dose inhaler (pMDI) platform 1 Aiming to become the first pharmaceutical company to transition its broad pMDI portfolio to a next generation propellant,…

Parma, Italy and Villars-sur-Glâne SA, Switzerland, 11 August 2025 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, announced today that FILSUVEZ® (Oleogel-S10, dry extract from birch bark) was…